1. Shinozaki S, Kobayashi Y, et al. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion. 2021;102:319–325 .
2. Seicean R. Vonoprazan Versus Conventional Proton Pump Inhibitor in the Therapeutic Armamentarium of Peptic Ulcer Disease and Gastroesophageal Reflux Disease. IntechOpen. 2021;0:1-11.
3. Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int. 2019 May 9;2019:9781212.
4. Azlina M F N, Aishah C R N. Vonoprazan and Proton Pump Inhibitors in Helicobacter pylori Eradication Therapy: A Systematic Review. Sains Malaysiana. 2020;49(6):1371-1380.
5. Lertsirimunkong J, Thavornwattanayong W, et al. Cost-effectiveness Analysis Comparing Vonoprazan based Triple Therapy with Proton Pump Inhibitor based Therapy in the Treatment of Helicobacter pylori Infection in Thailand. Siriraj Med J. 2021;73:823-83
6. Sue S, Maeda S. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?. Gut Liver. 2021;15(6):799-810
7. Ohtaka M, Miura M, Hanawa M, et al. Efficacy and Tolerability of Second-Line Metronidazole Triple Therapy Using Vonoprazan for Helicobacter pylori Eradication in Japan—Comparative Study: Vonoprazan vs. Proton Pump Inhibitors. Open Journal of Gastroenterology 2018;8:27-38.
8. Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23(2):e12456.
9. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter. 2017;22(6):1-9.
10. Sue S, Shibata W, Sasaki T, et al. Randomized Trial of Vonoprazan- Versus PPI-Based Third-Line Triple Therapy With Sitafloxacin for Helicobacter pylori. Journal of Gastroenterology and Hepatology. 2019;0:1-23.
Facebook 
Masuk dengan Email
